We are an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders.
Joined August 2019
- Tweets 790
- Following 356
- Followers 3,466
- Likes 49
650 Photos and videos
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
bit.ly/4uNFxzH
$AIM #OvarianCancer #PancreaticCancer #BreastCancer #ColorectalCancer
145
Jun 15
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
bit.ly/43Vd0O1
$AIM #OvarianCancer #PancreaticCancer
1
543
Jun 9
#InCaseYouMissedIt: AIM ImmunoTech participated in a Virtual Investor KOL Connect featuring Professor Dr. Casper H.J. van Eijck and CEO Thomas Equels discussing Ampligen’s potential in late-stage pancreatic cancer.
Catch up here: vimeo.com/1192236396/29dc789…
$AIM #PancreaticCancer
1
551
Jun 9
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
bit.ly/4aDfLHb
$AIM
1
311
Jun 8
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
bit.ly/4ahtHXg
$AIM #PancreaticCancer #PanCan
1
3
598
Jun 5
June is #CancerSurvivorsMonth.
Every story represents moments that once felt uncertain, milestones worth celebrating and the hope that continues to move progress forward.
At $AIM, we remain with the goal of helping create a future with more stories of hope ahead.
#Oncology
1
250
AIM ImmunoTech retweeted
In a #WhatThisMeans segment, Tom Equels, Dr. Charles Lapp and Dr. Christopher Nicodemus, examine current Ebola outbreak concerns, the unmet need surrounding the Bundibugyo strain, and Ampligen’s previously published antiviral research.
🔗: vimeo.com/1198375699/68d52d4…
$AIM #Ebola
1
2
1,020
Jun 4
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
bit.ly/4x7NRgj
$AIM #VirtualInvestor #OvarianCancer #PancreaticCancer #BreastCancer #ColorectalCancer
2
4
649
Jun 1
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
bit.ly/43FiQCN
$AIM #VirtualInvestor #OvarianCancer #PancreaticCancer #BreastCancer #ColorectalCancer
1
6
809
May 27
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
bit.ly/4nVwOtE
$AIM #CancerResearch #PancreaticCancer #BreastCancer
5
4
8
1,305
May 20
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
bit.ly/4v0QNth
$AIM
1
1
2
476
May 20
An estimated 150K people lose their lives to late-stage pancreatic cancer each year.
In the latest Closing Bell segment, CEO Thomas Equels discusses how $AIM is working to address this significant unmet need.
Hear more: bit.ly/48qWYhf
#CancerResearch #Oncology
2
1
440
May 19
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
bit.ly/49YMYwq
$AIM #CancerResearch #Oncology
1
317
May 15
Stay up to date with the latest from $AIM.
Sign up for email alerts to receive company news and research updates directly to your inbox:
bit.ly/3rp8t3N
#CancerResearch #Oncology
162
May 14
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
bit.ly/4eLGQeu
$AIM #CancerResearch #Oncology
1
134
May 13
In our latest Closing Bell segment, CEO Thomas Equels highlighted our strategic focus on Ampligen, supported by promising clinical data and broad potential across key indications.
Watch here: bit.ly/48qWYhf
$AIM #CancerResearch #Oncology
5
286
May 11
May is National Cancer Research Month, highlighting the progress shaping the future of oncology.
At $AIM, we are advancing an immune-based therapy to address critical unmet needs in cancer care.
#CancerResearch #Oncology
2
1
229
May 8
Today on World Ovarian Cancer Day, we stand with the women impacted by this disease and honor those still battling.
Together, we AIM for more survivors. We AIM for a cure.
$AIM #WorldOvarianCancerDay #OvarianCancerAwareness #BetterTreatments #BrighterFutures #NoWomanLeftBehind
1
1
450
May 8
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
bit.ly/3QZUP6m
$AIM
2
212
May 8
On World Ovarian Cancer Day, we stand with patients and advocates working to raise awareness for a disease often diagnosed too late.
We remain committed to advancing research to improve outcomes.
$AIM #CancerResearch #Oncology
1
162